NeurAxis Adds 1.25M Covered Lives with Four New Insurer Policies
NeurAxis gained medical policy coverage from four additional insurers for its IB-Stim PENFS device, adding about 1.25 million covered lives in West Virginia, New Hampshire, South Carolina, Virginia and Florida. The company’s 2025 financial statements include an emphasis-of-matter expressing substantial doubt about its ability to continue as a going concern.
1. Coverage Expansion Details
NeurAxis secured medical policy coverage from four additional health insurers for its IB-Stim PENFS device, adding about 1.25 million covered lives across West Virginia, New Hampshire, South Carolina, Virginia and Florida.
2. Commercial Impact
Expanded coverage may boost IB-Stim adoption and revenue by improving patient access in those five states, supporting the company’s growth strategy and potential market penetration for its neuromodulation therapy.
3. Going Concern Disclosure
The company’s 2025 financial statements include an emphasis-of-matter expressing substantial doubt about its ability to continue as a going concern, highlighting liquidity risks that investors should monitor.